Everolimus inhibits the bone-resorbing activity of osteoclasts. Murine bone marrow-derived mononuclear cells were differentiated to osteoclasts on bone slices in vitro before being treated with everolimus at concentrations of 1, 10, and 100 nM for 5 days in total. On day 5, supernatants were collected and analyzed for the levels of the bone resorption marker collagen type I cross-linked C-telopeptide (CTx). Data were analyzed using one-way ANOVA and the Bonferroni posttest, and significance between the control and everolimus concentrations is denoted (** p